Skip to main content
芭薇股份 logo

芭薇股份 — Investor Relations & Filings

Ticker · 920123 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 240 across all filing types
Latest filing 2024-04-25 Governance Information
Country CN China
Listing Beijing Stock Exchange 920123

About 芭薇股份

https://www.gzbawei.com/

Guangdong Bawei Biotechnology Corp., Ltd. is a comprehensive beauty and personal care solution provider specializing in research, development, production, and testing. The company offers integrated OEM, ODM, and OBM services, covering a wide range of product categories including skincare, hair care, body care, and makeup. Bawei is recognized for its commitment to scientific innovation, operating advanced R&D laboratories and an independent third-party testing center that ensures product safety and efficacy. By leveraging automated production lines and a rigorous quality management system, the company serves a diverse portfolio of domestic and international brands. Its core focus remains on delivering high-quality, customized formulations and manufacturing excellence to meet evolving consumer demands in the global beauty market.

Recent filings

Filing Released Lang Actions
关联交易管理办法
Governance Information Classification · 95% confidence The document is titled "广东芭薇生物科技股份有限公司关联交易管理办法" which translates to "Related Party Transaction Management Measures". It is a detailed policy document outlining the management, approval, pricing, disclosure, and governance of related party transactions within the company. The document includes references to regulatory compliance with Chinese securities laws and stock exchange rules, detailed procedural rules for board and shareholder approvals, and disclosure requirements. It is not a financial report, earnings release, or announcement of voting results. It is also not a proxy solicitation or remuneration report. The document is a governance-related policy document issued by the board and approved by the shareholders, focusing on internal rules and governance practices related to related party transactions. Therefore, the most appropriate classification is Governance Information (CGR). The document length (7164 characters) and content confirm it is a full policy document, not a brief announcement or certification.
2024-04-25 Chinese
2023 年年度权益分派预案公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as an "Annual Equity Distribution Plan Announcement" for the year 2023 by Guangdong Bawei Biotechnology Co., Ltd. It details the proposed dividend distribution plan based on the audited 2023 annual report, including the dividend amount, board and supervisory committee approvals, and references to the company's articles of association regarding profit distribution. The document is an announcement of the dividend plan (equity distribution) and not the full annual report itself. It also mentions that the plan is subject to approval at the 2023 annual shareholders meeting. The document length is 2315 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of "Notice of Dividend Amount" (DIV), which covers announcements of dividend amounts, payment dates, and related details for shareholders.
2024-04-25 Chinese
股东大会议事规则
Governance Information Classification · 95% confidence The document is titled as "股东大会议事规则" which translates to "Shareholders' Meeting Rules" or "Rules of Procedure for the Shareholders' General Meeting". It details the procedures, rules, and regulations governing the conduct of shareholders' meetings, including the rights and responsibilities of shareholders, the board, and other parties involved. It references legal frameworks and company bylaws but does not contain financial statements, audit results, voting results, or announcements of meetings. It is a governance-related document outlining internal rules and practices for shareholder meetings. Therefore, it fits best under Governance Information (CGR). The document length is 8326 characters, indicating it is a full document, not a brief announcement or notice.
2024-04-25 Chinese
年报信息披露重大差错责任追究制度
Regulatory Filings Classification · 95% confidence The document is titled as a "重大差错责任追究制度" which translates to "Major Error Responsibility Pursuit System" related to the company's annual report information disclosure. It outlines the principles, standards, and procedures for handling significant errors in the annual report disclosures, including responsibilities and penalties for involved personnel. The document does not contain actual financial statements or financial data but rather describes internal control policies and accountability mechanisms regarding annual report disclosures. It is a regulatory or compliance-related announcement about the company's internal system for managing errors in annual reports, not the annual report itself or a financial report. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance document related to disclosure practices and error management, not the annual report or audit report itself.
2024-04-25 Chinese
2023 年度独立董事述职报告（蔡光云）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2023 by an independent director of Guangdong Bawi Biotechnology Co., Ltd. It details the director's duties, attendance at meetings, communication with internal audit and auditors, on-site work, investor protection efforts, self-evaluation, and suggestions. The content focuses on the director's role and activities rather than financial results or audit opinions. It is a report by a board member about their management and governance role, not a full annual report, audit report, or earnings release. This fits the category of Board/Management Information (MANG), which covers announcements related to board members and senior management activities and reports. The document length is 2610 characters, which is relatively short but contains substantive content about the director's duties and activities, not just an announcement or notice. Therefore, the best classification is MANG with high confidence.
2024-04-25 Chinese
董事会议事规则
Governance Information Classification · 100% confidence The document is titled "广东芭薇生物科技股份有限公司董事会议事规则" which translates to "Rules of Procedure for the Board of Directors of Guangdong Bawei Biotechnology Co., Ltd." It details the internal rules, procedures, and governance practices for the company's board meetings, including meeting notices, voting procedures, committee structures, and record keeping. There is no financial data, earnings information, or announcements of voting results. The content is focused on governance and board management rules. Therefore, the document fits the category of Governance Information (CGR). The document length is 6737 characters, indicating it is a full document, not a brief announcement or certification.
2024-04-25 Chinese

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.